Clinical trials using psychedelic substances such as MDMA, marijuana, ketamine and psilocybin to combat mental and physical illnesses can only commence after years of regulatory and ethical hurdle-leaping and face many more before those medicines may be licensed. The impact of the classification of psychedelic substances as having no accepted medical use on the regulatory systems governing clinical research and licensing in the US, Europe and the UK will be considered and possible solutions to the legal impasse will be offered.
|Published - 2 Jul 2017
|Breaking Convention 2017 - London
Duration: 2 Jul 2017 → …
|Breaking Convention 2017
|2/07/17 → …